Animal Component-Free Cell Dissociation Kit

Dissociation kit for human stem and progenitor cells

产品优势


  • Optimized for the dissociation and passaging of human stem
    and progenitor cells

  • Obtain cleaner cultures with ready-to-use, animal component-free solutions

  • Use Animal Component-Free Dissociation Kit for dissociating and passaging human stem and progenitor cells. Compatible with cells cultured in various media formulations, this kit comes with ready-to-use solutions, including ACF Enzymatic Dissociation Solution and ACF Enzyme Inhibition Solution.

    Previously known as MesenCult™-ACF Dissociation Kit, this kit's name was changed to accommodate the use of this product with other cell types such as endothelial cells, HUVECs, mesenchymal cells, PSC-derived cells, mesenchymal stem and progenitor cells, and myogenic stem and progenitor cells.
    未找到

    Protocols and Documentation

    Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

    Document Type
    Product Name
    Catalog #
    Lot #
    Language
    Catalog #
    05426
    Lot #
    All
    Language
    English
    Document Type
    Safety Data Sheet 1
    Catalog #
    05426
    Lot #
    All
    Language
    English
    Document Type
    Safety Data Sheet 2
    Catalog #
    05426
    Lot #
    All
    Language
    English

    Applications

    This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

    Resources and Publications

    Educational Materials (8)

    Publications (2)

    Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells. Aanei CM et al. Experimental cell research 2011 NOV

    Abstract

    Direct cell-cell contact between haematopoietic progenitor cells (HPCs) and their cellular microenvironment is essential to maintain 'stemness'. In cancer biology, focal adhesion (FA) proteins are involved in survival signal transduction in a wide variety of human tumours. To define the role of FA proteins in the haematopoietic microenvironment of myelodysplastic syndromes (MDS), CD73-positive mesenchymal stromal cells (MSCs) were immunostained for paxillin, pFAK [Y(397)], and HSP90α/β and p130CAS, and analysed for reactivity, intensity and cellular localisation. Immunofluorescence microscopy allowed us to identify qualitative and quantitative differences, and subcellular localisation analysis revealed that in pathological MSCs, paxillin, pFAK [Y(397)], and HSP90α/β formed nuclear molecular complexes. Increased expression of paxillin, pFAK [Y(397)], and HSP90α/β and enhanced nuclear co-localisation of these proteins correlated with a consistent proliferative advantage in MSCs from patients with refractory anaemia with excess blasts (RAEB) and negatively impacted clonogenicity of HPCs. These results suggest that signalling via FA proteins could be implicated in HPC-MSC interactions. Further, because FAK is an HSP90α/β client protein, these results suggest the utility of HSP90α/β inhibition as a target for adjuvant therapy for myelodysplasia.
    Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Dominici M et al. Cytotherapy 2006 JAN

    Abstract

    The considerable therapeutic potential of human multipotent mesenchymal stromal cells (MSC) has generated markedly increasing interest in a wide variety of biomedical disciplines. However, investigators report studies of MSC using different methods of isolation and expansion, and different approaches to characterizing the cells. Thus it is increasingly difficult to compare and contrast study outcomes, which hinders progress in the field. To begin to address this issue, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC. First, MSC must be plastic-adherent when maintained in standard culture conditions. Second, MSC must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules. Third, MSC must differentiate to osteoblasts, adipocytes and chondroblasts in vitro. While these criteria will probably require modification as new knowledge unfolds, we believe this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.
    PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.
    版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。